Search

Your search keyword '"Julius Lindblom"' showing total 15 results
Start Over Author "Julius Lindblom" Topic rc581-607
15 results on '"Julius Lindblom"'

4. O15 B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separate neuropsychiatric systemic lupus erythematosus patients into two distinct subgroups with differential anticipated response to targeted therapies

Author

Lorenzo Beretta, Maria Orietta Borghi, Ioannis Parodis, Dionysis Nikolopoulos, Marta E Alarcón-Riquelme, Yvonne Enman, Guillermo Barturen, Daniel Toro-Domínguez, Elena Carnero-Montoro, Chandra Mohan, Ellen Iacobaeus, Julius Lindblom, and Jessica Castillo

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2024
Full Text
View/download PDF

6. O23 Interferon upregulation and B and plasma cell gene dysregulation patterns reveal three distinct lupus nephritis subgroups with differential anticipated response to targeted therapies

Author

Lorenzo Beretta, Maria Orietta Borghi, Ioannis Parodis, Dionysis Nikolopoulos, Marta E Alarcón-Riquelme, Yvonne Enman, Guillermo Barturen, Daniel Toro-Domínguez, Elena Carnero-Montoro, Chandra Mohan, Julius Lindblom, and Jessica Castillo

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2024
Full Text
View/download PDF

11. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus

Author

Julius Lindblom, Lorenzo Beretta, Maria Orietta Borghi, PRECISESADS Clinical Consortium, Marta E. Alarcón-Riquelme, Ioannis Parodis, Barbara Vigone, Jacques-Olivier Pers, Alain Saraux, Valérie Devauchelle-Pensec, Divi Cornec, Sandrine Jousse-Joulin, Bernard Lauwerys, Julie Ducreux, Anne-Lise Maudoux, Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, Raquel Faria, Mariana Brandão, Ana Campar, António Marinho, Farinha Fátima, Isabel Almeida, Angel Gonzalez-Gay Mantecón, Ricardo Blanco Alonso, Alfonso Corrales Martínez, Ricard Cervera, Ignasi Rodríguez-Pintó, Gerard Espinosa, Rik Lories, Ellen De Langhe, Nicolas Hunzelmann, Doreen Belz, Torsten Witte, Niklas Baerlecken, Georg Stummvoll, Michael Zauner, Michaela Lehner, Eduardo Collantes, Rafaela Ortega-Castro, MaAngeles Aguirre-Zamorano, Alejandro Escudero-Contreras, MaCarmen Castro-Villegas, Norberto Ortego, María Concepción Fernández Roldán, Enrique Raya, Inmaculada Jiménez Moleón, Enrique de Ramon, Isabel Díaz Quintero, Pier Luigi Meroni, Maria Gerosa, Tommaso Schioppo, Carolina Artusi, Carlo Chizzolini, Aleksandra Zuber, Donatienne Wynar, Laszló Kovács, Attila Balog, Magdolna Deák, Márta Bocskai, Sonja Dulic, Gabriella Kádár, Falk Hiepe, Velia Gerl, Silvia Thiel, Manuel Rodriguez Maresca, Antonio López-Berrio, Rocío Aguilar-Quesada, and Héctor Navarro-Linares.

Subjects
autoimmunity, systemic lupus erythematosus, antiphospholipid syndrome, diagnosis, biomarkers, cytokines, Immunologic diseases. Allergy, RC581-607
Abstract

IntroductionSystemic lupus erythematosus (SLE) is a clinically heterogeneous disease that presents a challenge for clinicians. To identify potential biomarkers for diagnosis and disease activity in SLE, we investigated a selected yet broad panel of cytokines and autoantibodies in patients with SLE, healthy controls (HC), and patients with other autoimmune diseases (AIDs).MethodsSerum samples from 422 SLE patients, 546 HC, and 1223 other AIDs were analysed within the frame of the European PRECISESADS project (NTC02890121). Cytokine levels were determined using Luminex panels, and autoantibodies using different immunoassays.ResultsOf the 83 cytokines analysed, 29 differed significantly between patients with SLE and HC. Specifically, CCL8, CXCL13, and IL-1RA levels were elevated in patients with active, but not inactive, SLE versus HC, as well as in patients with SLE versus other AIDs. The levels of these cytokines also correlated with SLE Disease Activity Index 2000 (SLEDAI-2K) scores, among five other cytokines. Overall, the occurrence of autoantibodies was similar across SLEDAI-2K organ domains, and the correlations between autoantibodies and activity in different organ domains were weak.DiscussionOur findings suggest that, upon validation, CCL8, CXCL13, and IL-1RA could serve as promising serum biomarkers of activity in SLE.

Published
2023
Full Text
View/download PDF

14. LO-019 Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 vaccination in autoimmune disease (COVAD) study

Author

Rohit Aggarwal, Hector Chinoy, John Pauling, Yi-Ming Chen, Chris Wincup, Ioannis Parodis, Elena Nikiphorou, Latika Gupta, James Lilleker, Vishwesh Agarwal, Vikas Agarwal, Wanruchada Katchamart, Arvind Nune, Julius Lindblom, Emelie Khilgren Olsson, R Naveen, Sreoshy Saha, Syahrul Sazliyana Shaharir, Phonpen Akarawatcharangura Goo, Lisa Traboco, Kshitij Jagtap, Dey Dzifa, Carlos Enrique Toro Gutierrez, and Carlo Vinicio Caballero

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2023
Full Text
View/download PDF

15. Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab

Author

Ioannis Parodis, Alvaro Gomez, Jun Weng Chow, Alexander Borg, Julius Lindblom, and Mariele Gatto

Subjects
systemic lupus erythematosus, biomarkers, flares, plasma cells, B cells, belimumab, Immunologic diseases. Allergy, RC581-607
Abstract

ObjectiveTo investigate changes in B cell subsets in relation to disease flares upon initiation of standard therapy (ST) plus belimumab or placebo in patients with systemic lupus erythematosus (SLE).Patients and MethodsUsing data from the BLISS-76, BLISS-SC and BLISS Northeast Asia trials, we investigated associations of relative to baseline rapid (through week 8) and early (through week 24) changes in peripheral B cell subsets, anti-dsDNA and complement levels with the occurrence of disease flares from week 24 through week 52 (Mann-Whitney U tests) or the entire study follow-up (Cox regression analysis), assessed using the SELENA-SLEDAI Flare Index.ResultsPatients on ST alone who flared displayed less prominent early decreases in CD19+CD20-CD138+ long-lived plasma cells (-16.1% versus -35.1%; P=0.012). In all arms combined, patients who developed severe flares showed less prominent early decreases in CD19+CD20-CD138+ long-lived plasma cells (-23.5% versus -39.4%; P=0.028) and CD19+CD27brightCD38bright SLE-associated plasma cells (-19.0% versus -27.8%; P=0.045). After adjustment for rapid changes, early increases in overall CD19+CD20+ B cells (HR: 1.81; 95% CI: 1.08–3.05; P=0.024) and early increases or no return after a rapid expansion in CD19+CD20+CD27+ memory B cells (HR: 1.58; 95% CI: 1.18–2.11; P=0.002) portended subsequent severe flares. Patients who developed flares of any severity showed no or less prominent rapid (0.0% versus -12.5%; P

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results